Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer

The HELPP Score: A Pretreatment Prognostic Score to Predict Survival and Patterns of Recurrence in Localized Non-Metastatic Pancreatic Cancer - a Multicenter Prospective Validation Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma. The main questions it aims to answer are: * Is the HELPP score able to predict median overall survival in a prospective multi-institutional cohort of patients with pretherapeutic localized non-metastatic pancreatic cancer? * Is the HELPP score able to predict median recurrence-free survival and patterns of recurrence after resection of pancreatic cancer?

Who May Be Eligible (Plain English)

Who May Qualify: - ≥18 years old - fit to undergo elective pancreatic resection or palliative therapy - localized non-metastatic pancreatic ductal adenocarcinoma - willing to sign a consent form provided Who Should NOT Join This Trial: - patients with a diagnosis other than pancreatic ductal adenocarcinoma on histopathology - missing willing to sign a consent form - missing mandatory pretreatment laboratory values - missing mandatory pretreatment clinicopathologic data - patients receiving surgery for peripancreatic cancer - incomplete follow-up records - follow-up \< 24 months - pregnancy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * ≥18 years old * fit to undergo elective pancreatic resection or palliative therapy * localized non-metastatic pancreatic ductal adenocarcinoma * informed consent provided Exclusion Criteria: * patients with a diagnosis other than pancreatic ductal adenocarcinoma on histopathology * missing informed consent * missing mandatory pretreatment laboratory values * missing mandatory pretreatment clinicopathologic data * patients receiving surgery for peripancreatic cancer * incomplete follow-up records * follow-up \< 24 months * pregnancy

Locations (1)

Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna
Vienna, Austria